跳至主要内容

Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson’s

ABSTRACT
A randomized, double blind, and active reference-controlled study was carried out among 116 patients suffering from idiopathic Parkinson’s disease (PD). The aim of the study was to compare the safety and efficacy of alpha-dihydroergocryptine (DHEC) vs. pramipexole (PRAM) as an adjunct symptomatic therapy to levodopa in PD patients. The motor symptoms, assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) III subscale, was identified as efficacy target. Fifty-six patients were randomized to DHEC and 60 to PRAM. Patients included were under constant levodopa dose for at least 3 months before entering the study, with baseline UPDRS III ≥14. They underwent a 16-week treatment. Out of the 116 included patients, 85 (39 in DHEC group and 46 in PRAM group, respectively) completed the study protocol. In DHEC group, UPDRS III decreased by 24.2% from baseline at week 10 and by 28.1% at week 16. In PRAM group, UPDRS III decreased by 27.1% from baseline at week 10 and by 29.2% at week 16. The data were highly significant (p < 0.01) at each time point versus baseline, while no significant difference was noticed between treatments. Overall, the patient population did not show any clinically meaningful mood disturbances at baseline and the fluctuations of UPDRS I during treatment were devoid of clinical significance. Safety was fairly good in both groups. In conclusion, DHEC and PRAM proved to be effective and safe as adjunct therapy to levodopa in idiopathic PD. According to the research result, they have significantly improved the motor function of our patients.
 
Cite this paper
Ortiz, U. , Juan, D. and Scarci, F. (2015) Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson’s. Advances in Parkinson's Disease, 4, 1-8. doi: 10.4236/apd.2015.41001.
 
References
[1]Stacy, M. and Galbreath, A. (2008) Optimizing Long-Term Therapy for Parkinson Disease: Levodopa, Dopamine Agonists, and Treatment-Associated Dyskinesia. Clinical Neuropharmacology, 31, 51-56. http://dx.doi.org/10.1097/WNF.0b013e318065b088
 
[2]Hauser, R.A., Rascol, O., Korczyn, A.D., et al. (2007) Ten-Year Follow-Up of Parkinson’s Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa. Movement Disorders, 22, 2409-2417. http://dx.doi.org/10.1002/mds.21743
 
[3]The Parkinson Study Group CALM Cohort Investigators (2009) Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease. Archives of Neurology, 66, 563-570. http://dx.doi.org/10.1001/archneurol.2009.32
 
[4]Goetz, C.G., Poewe, W., Rascol, O. and Sampaio, C. (2005) Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson’s Disease: 2001 to 2004. Movement Disorders, 20, 523-539. http://dx.doi.org/10.1002/mds.20464
 
[5]Andrejak, M. and Tribouilloy, C. (2013) Drug-Induced Valvular Heart Disease: An Update. Archives of Cardiovascular Diseases, 106, 333-339. http://dx.doi.org/10.1016/j.acvd.2013.02.003
 
[6]Bergamasco, B., Frattola, L., Muratorio, A., et al. (2000) Alpha-Dihydroergocryptine in the Treatment of de novo parkinsonian Patients: Results of a Multicentre, Randomized, Double-Blind, Placebo-Controlled Study. Acta Neurologica Scandinavica, 101, 372-380. http://dx.doi.org/10.1034/j.1600-0404.2000.90295a.x
 
[7]Battistin, L., Bardin, P.G., Ferro-Milone, F., et al. (1999) Alpha-Dihydroergocryptine in Parkinson’s Disease: A Multicentre Randomized Double Blind Parallel Group Study. Acta Neurologica Scandinavica, 99, 36-42. http://dx.doi.org/10.1111/j.1600-0404.1999.tb00655.x
 
[8](2008) Questions and Answers on the Review of Ergot-Derived Dopamine Agonists, Ref. EMEA/CHMP/319054/2008.
 
[9]Bonuccelli, U., D’Antonio, P., D’Avino, C., et al. (1995) Dihydroergocryptine in the Treatment of Parkinson’s Disease. Journal of Neural Transmission, 45, 239-245.
 
[10]Parkinson Study Group (1997) Safety and Efficacy of Pramipexole in Early Parkinson Disease. A Randomized Dose- Ranging Study. JAMA, 278, 125-130. http://dx.doi.org/10.1001/jama.1997.03550020057038
 
[11]Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA, 284, 1931-1938. http://dx.doi.org/10.1001/jama.284.15.1931                  eww150113lx
 
[12]Rascol, O., Payoux, P., Ferreira, J. and Brefel-Courbon, C. (2002) The Management of Patients with Early Parkinson’s Disease. Parkinsonism Relat Disord, 9, 61-67. http://dx.doi.org/10.1016/S1353-8020(02)00045-7
 
[13]MHRA Public Assessment Report (2007) Dopamine Agonists: Pathological Gambling and Increased Libido.
标签：

评论

发表评论

此博客中的热门博文

A Comparison of Methods Used to Determine the Oleic/Linoleic Acid Ratio in Cultivated Peanut (Arachis hypogaea L.)

Cultivated peanut ( Arachis hypogaea L.) is an important oil and food crop. It is also a cheap source of protein, a good source of essential vitamins and minerals, and a component of many food products. The fatty acid composition of peanuts has become increasingly important with the realization that oleic acid content significantly affects the development of rancidity. And oil content of peanuts significantly affects flavor and shelf-life. Early generation screening of breeding lines for high oleic acid content greatly increases the efficiency of developing new peanut varieties. The objective of this study was to compare the accuracy of methods used to classify individual peanut seed as high oleic or not high oleic. Three hundred and seventy-four (374) seeds, spanning twenty-three (23) genotypes varying in oil composition (i.e. high oleic (H) or normal/not high oleic (NH) inclusive of all four peanut market-types (runner, Spanish, Valencia and Virginia), were individually tested ...
发表评论
阅读全文

Location Optimization of a Coal Power Plant to Balance Costs against Plant’s Emission Exposure

Fuel and its delivery cost comprise the biggest expense in coal power plant operations. Delivery of electricity from generation to consumers requires investment in power lines and transmission grids. Placing a coal power plant or multiple power plants near dense population centers can lower transmission costs. If a coalmine is nearby, transportation costs can also be reduced. However, emissions from coal plants play a key role in worsening health crises in many countries. And coal upon combustion produces CO 2 , SO 2 , NO x , CO, Metallic and Particle Matter (PM10 & PM2.5). The presence of these chemical compounds in the atmosphere in close vicinity to humans, livestock, and agriculture carries detrimental health consequences. The goal of the research was to develop a methodology to minimize the public’s exposure to harmful emissions from coal power plants while maintaining minimal operational costs related to electric distribution losses and coal logistics. The objective was...
发表评论
阅读全文

Evaluation of the Safety and Efficacy of Continuous Use of a Home-Use High-Frequency Facial Treatment Appliance

At present, many home-use beauty devices are available in the market. In particular, many products developed for facial treatment use light, e.g., a flash lamp or a light-emitting diode (LED). In this study, the safety of 4 weeks’ continuous use of NEWA TM , a high-frequency facial treatment appliance, every alternate day at home was verified, and its efficacy was evaluated in Japanese individuals with healthy skin aged 30 years or older who complained of sagging of the facial skin.  Transepidermal water loss (TEWL), melanin levels, erythema levels, sebum secretion levels, skin color changes and wrinkle improvement in the facial skin were measured before the appliance began to be used (study baseline), at 2 and 4 weeks after it had begun to be used, and at 2 weeks after completion of the 4-week treatment period (6 weeks from the study baseline). In addition, data obtained by subjective evaluation by the subjects themselves on a visual analog scale (VAS) were also analyzed. Fur...
发表评论
阅读全文